Nakhaie S, Yazdani R, Shakibi M, Torabian S, Pezeshki S, Bazrafshani MS, et al. The effects of antihypertensive medications on severity and outcomes of hypertensive patients with COVID-19. J Hum Hypertens. (in press).

Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14–20.

CAS  Article  Google Scholar 

Sidarta-Oliveira D, Jara CP, Ferruzzi AJ, Skaf MS, Velander WH, Araujo EP, et al. SARS-CoV-2 receptor is co-expressed with elements of the kinin–kallikrein, renin–angiotensin and coagulation systems in alveolar cells. Sci Rep. 2020;10:19522. https://doi.org/10.1038/s41598-020-76488-2.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Tabassum A, Iqbal MS, Sultan S, Alhuthali RA, Alshubaili DI, Sayyam RS, et al. Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19. Mediators Inflamm. 2022;2022:7423537. https://doi.org/10.1155/2022/7423537.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Azevedo RB, Botelho BG, Hollanda JVG, Ferreira LVL, Junqueira de Andrade LZ, Oei SSML. et al. COVID19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35:4–11.

CAS  Article  Google Scholar 

Işık F, Çap M, Akyüz A, Bilge Ö, Aslan B, İnci Ü, et al. The effect of resistant hypertension on in-hospital mortality in patients hospitalized with COVID-19. J Hum Hypertens. 2021;5:1–6. https://doi.org/10.1038/s41371-021-00591-8.

Sheppard JP, Nicholson BD, Lee J, McGagh D, Sherlock J, Koshiaris C, et al. Association between blood pressure control and coronavirus disease 2019 outcomes in 45 418 symptomatic patients with hypertension: an observational cohort study. Hypertension. 2021;77:846–55.

CAS  Article  Google Scholar 

Ware LB. Physiological and biological heterogeneity in COVID19-associated acute respiratory distress syndrome. Lancet Respir Med. 2020;8:1163–5.

CAS  Article  Google Scholar 

Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194–202.

CAS  Article  Google Scholar 

Kunal S, Gupta K, Sharma SM, Pathak V, Mittal S, Tarke C. Cardiovascular system and COVID-19: perspectives from a developing country. Monaldi Arch Chest Dis. 2020;7:90. https://doi.org/10.4081/monaldi.2020.1305.

El-Saber Batiha G, Al-Gareeb AI, Saad HM, Al-Kuraishy HM. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022;13:1–17. https://doi.org/10.1007/s10787-022-00987-z.

Article  Google Scholar 

Gormez S, Ekicibasi E, Degirmencioglu A, Paudel A, Erdim R, Gumusel HK, et al. Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID19in hospitalized patients: a multicenter, observational study. J Hum Hypertens. 2021;35:588–97. https://doi.org/10.1038/s41371-020-00405-3.

CAS  Article  PubMed  Google Scholar 

Angeli F, Verdecchia P, Balestrino A, Bruschi C, Ceriana P, Chiovato L, et al. Renin angiotensin system blockers and risk of mortality in hypertensive patients hospitalized for COVID-19: an Italian registry. J Cardiovasc Dev Dis. 2022;9:15. https://doi.org/10.3390/jcdd9010015.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Mansour E, Palma AC, Ulaf RG, Ribeiro LC, Bernardes AF, Nunes TA, et al. Safety and outcomes associated with the pharmacological inhibition of the Kinin-Kallikrein system in severe COVID-19. Viruses. 2021;13:309. https://doi.org/10.3390/v13020309.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Black LP, et al. Angiotensin receptor blocker based lung protective strategies for inpatients with COVID-19 (ALPS-IP) investigators. Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: a randomized clinical trial. JAMA Netw Open. 2022;5:e222735. https://doi.org/10.1001/jamanetworkopen.2022.2735.

Article  PubMed  PubMed Central  Google Scholar 

Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, et al. Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine. 2021;37:100962. https://doi.org/10.1016/j.eclinm.2021.100962.

Article  PubMed  PubMed Central  Google Scholar 

Amat-Santos IJ, Santos-Martinez S, López-Otero D, Nombela-Franco L, Gutiérrez-Ibanes E, Del Valle R, et al. Ramipril in high-risk patients with COVID-19. J Am Coll Cardiol. 2020;76:268–76. https://doi.org/10.1016/j.jacc.2020.05.040.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, et al. ACEI-COVID investigators. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID19(ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med. 2021;9:863–72.

CAS  Article  Google Scholar 

Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet. Respir Med. 2021;9:275–84. https://doi.org/10.1016/S2213-2600(20)30558-0.

CAS  Article  Google Scholar 

Lopes RD, Macedo AVS, de Barros E, Silva PGM, Moll-Bernardes RJ, Dos Santos TM, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325:254–64.

CAS  Article  Google Scholar 

Najmeddin F, Solhjoo M, Ashraf H, Salehi M, Rasooli F, Ghoghaei M, et al. Effects of Renin-Angiotensin-Aldosterone inhibitors on early outcomes of hypertensive COVID-19 patients: A Randomized Triple-Blind Clinical Trial. Am J Hypertens. 2021; https://doi.org/10.1093/ajh/hpab111.

Nouri-Vaskeh M, Kalami N, Zand R, Soroureddin Z, Varshochi M, Ansarin K, et al. Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial. Int J Clin Pract. 2021; https://doi.org/10.1111/ijcp.14124.

Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association between Renin-Angiotensin-Aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Netw Open. 2021; https://doi.org/10.1001/jamanetworkopen.2021.3594.

Sattar Y, Mukuntharaj P, Zghouzi M, Suleiman AM, Attique H, Ullah W, et al. Safety and efficacy of Renin-Angiotensin-Aldosterone system inhibitors in COVID-19 population. High Blood Press Cardiovasc Prev. 2021;28:405–16.

CAS  Article  Google Scholar 

Ferrari F, Martins VM, Fuchs FD, Stein R. Renin-Angiotensin-Aldosterone system inhibitors in COVID-19: a review. Clinics (Sao Paulo) 2021; https://doi.org/10.6061/clinics/2021/e2342.

Singh R, Rathore SS, Khan H, Bhurwal A, Sheraton M, Ghosh P, et al. Mortality and severity in COVID19 patients on ACEIs and ARBs-A systematic review, meta-analysis, and meta-regression analysis. Front Med (Lausanne). 2022; https://doi.org/10.3389/fmed.2021.703661.

Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020;43:1028–46.

CAS  Article  Google Scholar